This week the headline appeared to have some tough news for RNA companies, but Alnylam remains undeterred about the potential of its treatments.» Read More
Illumina landed squarely on Karen Finerman’s trader radar Wednesday with the company in the cross hairs of a hostile bid from Roche.
Keith Moore, MKM Partners, discusses how to play Roche's hostile bid for gene sequencer, Illumin, saying ILMN is likely to fight the takeover. Also an update on SanDisk's earnings, with the Fast Money crew.
Fast Money trader Karen Finerman explains what's behind Roche's tender offer for Illumina; and the best way to play the biotech takeout trend.
CNBC's David Faber has the details on Roche's Illumina offer worth $44.50 per share in cash.
U.S. stock index futures struggled for direction Wednesday as investors digested a handful of corporate earnings and ahead of the Federal Reserve's policy statement.
Severin Schwan, CEO of Roche, made his first appearance on CNBC, to discuss the pharmaceutical giant's third quarter earnings.
Swiss pharmaceutical giant, Roche, is due to release its Q3 sales results on Thursday. Amit Roy, head of healthcare equity research at Nomura and Barath Subramanian, healthcare senior consultant at Frost & Sullivan, joined CNBC to discuss what we can expect, and how the pharmaceutical sector as a whole is holding up.
U.S. drug regulators approved a targeted skin cancer drug from Roche Holding, offering new hope for patients with the deadliest form of cancer after years of few options.
The fate of the world's best-selling cancer medicine is in the hands of the FDA. There's a lot at stake for Roche and the thousands of women who take the drug, reports CNBC's Hampton Pearson.
A look at how Roche has recently received a boost from regulators for its key medications, with Hal Barron, Roche chief medical officer.
These more targeted, or niche, drugs might only treats thousands, but they could yield higher success rates for patients and lower marketing costs for the industry.
Roche's cancer drug Avastin remains a growth driver for the company despite disappointing sales in the US and Europe as a result of regulatory restrictions, Chief Executive Severin Schwan told CNBC on Thursday.
With the markets on a decline, investors need to put money into value plays, said Rob Hoxton, president and CEO of Hoxton Financial, and Robert Auer, portfolio manager at Auer Growth Fund.
Markets are probably due for a pullback in the near-term, but for the first half of 2011, stock are going to move higher, said Andrew Kanaly, chairman of Kanaly Trust Company.
European shares are expected to open flat Friday, though concerns about the euro zone debt crisis linger and could weigh on markets.
The Food and Drug Administration rejected another new diet pill on Thursday, the latest setback in the quest to develop treatments for overweight Americans amid the nation’s obesity epidemic.
A handful of biopharma stocks could be pretty volatile this week and we're talking right up until Friday.
Deal making is officially back on with three major takeovers announced Monday. Where is the Fast Money finding alpha amid increasing acquisitions?
Results of a new study could change the way elderly patients with vision trouble are treated and have financial implications for Swiss drug giants Novartis and Roche.
Well, it didn't take long. A little more than a month after Roche swallowed Genentech, Dr. Susan Desmond-Hellmann may be headed out the door sooner than anyone thought.